Navigation Links
Worldwide Clinical Trials Emerges as Leading Global Contract Research Organization
Date:7/9/2008

- Provides expertise in high-growth therapeutic areas to pharmaceutical and

biotechnology companies

- Aggressive acquisition strategy over the last year

BEVERLY HILLS, Calif., July 9 /PRNewswire/ -- Worldwide Clinical Trials, Inc.("WCT"), formed by Dr. Neal R. Cutler and a team of scientists, today reached a milestone in establishing itself as a premier global contract research organization with the announcement that it has closed the acquisition of MediQuest, a contract research organization providing specialized clinical development services to biopharmaceutical companies. The MediQuest acquisition was the most recent of five acquisitions made by WCT over the last year including Evidence Clinical and Pharmaceutical Research LLC, Clinical Studies Management Group, Inc., Nottingham Clinical Research Limited and CEDRA Corporation. The five acquisitions extend WCT's global footprint to more than 30 countries.

WCT is a leading therapeutically focused contract research organization that applies deep therapeutic expertise to help customers achieve their drug development goals. WCT provides clinical consulting and Phase I-IV drug development services -- including clinical trial design, clinical operations, data management, biostatistics, medical affairs, safety/pharmacovigilance, Electronic Data Capture and Interactive Voice Response System technologies, regulatory affairs, quality assurance bioanalytical services (LC-MS-MS, ligand binding, biomarkers), and pharmacokinetics -- for global pharma, specialty pharma and biotech companies.

Formed in 2007 by Dr. Cutler in partnership with The Jordan Company, a leading private equity firm, the company focuses on complex, high-growth therapeutic areas with primary expertise in central nervous system, and cardiovascular disease, along with significant experience in chronic inflammatory disease, metabolic / endocrinology and oncology. As expertise in these areas continues to be in demand, Worldwide Clinical Trials has sought to broaden its business through strategic growth and a highly selective acquisition strategy of companies that complements its existing skill-set.

"The acquisitions we have completed to date significantly enhance our contract research organization capabilities and our ability to manage large, global trials, within our primary therapeutic areas of focus. That in turn positions us well for future growth," said Dr. Cutler. "We have effectively expanded our operations and significantly enhanced our ability to meet the global needs of pharma and biotech companies. Our presence in Eastern Europe and Russia, two of the most attractive growth regions for clinical trials, helps transform our business into a truly global contract research organization."

Dr. Cutler and his team have reunited under the name of their former company, Worldwide Clinical Trials, which they founded in 1994 and sold to UnitedHealth in 1999. Dr. Cutler is known for pioneering several revolutionary techniques that increased the quality, safety and speed of drug development.

About Worldwide Clinical Trials, Inc.

Worldwide Clinical Trials (http://www.wwctrials.com) is a full-service contract research organization (CRO) that is medically and scientifically focused on central nervous system (CNS) and cardiovascular disease. WCT delivers quality clinical trials with leading edge science and medicine to help clients think through design, methodology and regulatory issues that are unique to every development program. WCT provides highly focused CRO services in all phases of research -- worldwide.

About The Jordan Company

The Jordan Company (http://www.thejordancompany.com), founded in 1982, is a leading middle-market private equity firm with over $6 billion of assets under management and a successful track record of investing in and growing businesses across a wide range of industries. The firm's partners have been investing together for more than two decades, establishing The Jordan Company as one of the most experienced and stable investment teams in private equity. The investment team is supported by the firm's Operations Management Group, which initiates and supports operational improvements in portfolio companies. The firm generates deal flow through a well-developed network of sourcing relationships. Headquartered in New York, The Jordan Company also has offices in Chicago and Shanghai.


'/>"/>
SOURCE Worldwide Clinical Trials, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
3. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
4. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
5. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
6. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
7. REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
8. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
9. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
10. Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide
11. Starion Achieves Worldwide Distribution of Proprietary Tissue Welding Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... 2016   ViaCyte, Inc ., a leading, ... stem cell-derived islet replacement therapy for the treatment ... announced that ViaCyte and Janssen Biotech, Inc., one ... Johnson, have agreed to consolidate the assets of ... provides ViaCyte with an exclusive license to all ...
(Date:2/3/2016)... Mass., Feb. 3, 2016 Harvard Apparatus ... biotechnology company developing bioengineered organ implants for life-threatening ... announced that CEO Jim McGorry , will ... Conference on Tuesday, February 9, 2016 at ... City . HART,s presentation will be webcast ...
(Date:2/3/2016)... ... February 03, 2016 , ... StarNet Communications ... solutions today announced the addition of a powerful “Session Preview” feature to its ... current state of the remote Linux desktop or other applications (sessions) they have ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... aid in the rapid development and ongoing quality control of molecular assays targeting ... is extremely high,” Dr. Gregory R. Chiklis, President and CEO of ZeptoMetrix, relayed ...
Breaking Biology Technology:
(Date:1/20/2016)... , Jan. 20, 2016 A market that ... directly benefit from the explosion in genomics knowledge. Learn ... Sound Research. A range of dynamic trends are pushing ... - personalized medicine - pharmacogenomics - pathogen evolution - ... large markets - greater understanding of the role of ...
(Date:1/18/2016)... SAN JOSE, Calif. , Jan. 18, 2016 ... storage security software that simplifies the use and ... a technology and go-to-market partnership with American Cyber.  ... "American Cyber brings extensive experience leading transformational C4ISR ... missions implementing and integrating the latest proven technology ...
(Date:1/13/2016)... , January 13, 2016 /PRNewswire/ ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the addition ... Identification Market - Estimation & Forecast ...
Breaking Biology News(10 mins):